LIPO vs. GOVX, NERV, CLRB, MYNZ, CING, TRIB, BMRA, CRVO, IMNN, and ACXP
Should you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include GeoVax Labs (GOVX), Minerva Neurosciences (NERV), Cellectar Biosciences (CLRB), Mainz Biomed (MYNZ), Cingulate (CING), Trinity Biotech (TRIB), Biomerica (BMRA), CervoMed (CRVO), Imunon (IMNN), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry.
Lipella Pharmaceuticals vs.
Lipella Pharmaceuticals (NASDAQ:LIPO) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, community ranking, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.
GeoVax Labs has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -882.82%. Lipella Pharmaceuticals' return on equity of -192.33% beat GeoVax Labs' return on equity.
74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
GeoVax Labs received 23 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 96.00% of users gave GeoVax Labs an outperform vote.
Lipella Pharmaceuticals has higher revenue and earnings than GeoVax Labs.
In the previous week, Lipella Pharmaceuticals and Lipella Pharmaceuticals both had 1 articles in the media. Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled GeoVax Labs'average media sentiment score.
Lipella Pharmaceuticals currently has a consensus target price of $16.00, suggesting a potential upside of 409.55%. GeoVax Labs has a consensus target price of $14.20, suggesting a potential upside of 747.76%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Lipella Pharmaceuticals.
Lipella Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.28, suggesting that its stock price is 228% more volatile than the S&P 500.
Summary
GeoVax Labs beats Lipella Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Lipella Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipella Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LIPO) was last updated on 2/22/2025 by MarketBeat.com Staff
Free LIPO Stock Alerts